Get the Stockscreener App
0.776
8.71%
-0.074
Pre-market:
.82
0.044
+5.67%
Fractyl Health Inc stock is traded at $0.776, with a volume of 6.89M.
It is down -8.71% in the last 24 hours and down -9.83% over the past month.
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
See More
Previous Close:
$0.85
Open:
$0.8696
24h Volume:
6.89M
Relative Volume:
3.53
Market Cap:
$123.11M
Revenue:
$3,000
Net Income/Loss:
$-108.00M
P/E Ratio:
-0.517
EPS:
-1.501
Net Cash Flow:
$-87.84M
1W Performance:
+16.85%
1M Performance:
-9.83%
6M Performance:
-64.07%
1Y Performance:
-62.87%
1-Day Range:
$0.776
$0.8696
1-Week Range:
$0.6777
$0.872
52-Week Range:
$0.3772
$2.445
Fractyl Health Inc Stock (GUTS) Company Profile
Name
Fractyl Health Inc
Sector
Industry
Phone
781-902-8800
Address
3 VAN DE GRAAFF DRIVE, BURLINGTON
Compare GUTS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GUTS
Fractyl Health Inc
|
0.776 | 134.85M | 3,000 | -108.00M | -87.84M | -1.501 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-15-25 | Initiated | H.C. Wainwright | Buy |
| Aug-28-25 | Initiated | Ladenburg Thalmann | Buy |
| Feb-28-24 | Initiated | Evercore ISI | Outperform |
| Feb-27-24 | Initiated | BofA Securities | Buy |
| Feb-27-24 | Initiated | Morgan Stanley | Overweight |
View All
Fractyl Health Inc Stock (GUTS) Latest News
GUTS SEC FilingsFractyl Health 10-K, 10-Q, 8-K Forms - Stock Titan
Fractyl Health director Ajay Royan buys $19,596 in company stock - Investing.com UK
Fractyl Health (NASDAQ: GUTS) director adds 23,000 shares in open-market buy - Stock Titan
Fractyl Health, Inc. 8-K Filing June 2026: Company Information, Nasdaq Listing, and Executive Details - Minichart
Fractyl Health Inc (GUTS) Cleared for RJVA-001 Trial. Let’s Look At Funding - Insider Monkey
Fractyl Health director William Bradley buys $50,328 in stock - Investing.com
Fractyl Health (NASDAQ: GUTS) 2026 meeting backs board and auditor - Stock Titan
Fractyl Health (GUTS) director buys stock and receives 22,500 options - Stock Titan
Fractyl Health (GUTS) awards 22,500 stock options to board director - Stock Titan
Fractyl Health (GUTS) awards director 22,500 options at $0.7318 - Stock Titan
Fractyl Health (GUTS) director Marc Elia receives 22,500-share stock option grant - Stock Titan
Fractyl Health (GUTS) director receives 22,500-stock-option board compensation grant - Stock Titan
Director Clive Meanwell gets 22,500 options at Fractyl Health (GUTS) - Stock Titan
Fractyl Health (NASDAQ: GUTS) director buys shares and receives options - Stock Titan
Fractyl Health (GUTS) CEO buys 25,000 open-market shares - Stock Titan
Fractyl Health CFO Smith Weber Lara purchases $13,708 in stock By Investing.com - Investing.com South Africa
Fractyl Health CFO Smith Weber Lara purchases $13,708 in stock - Investing.com
[Form 4] FRACTYL HEALTH, INC. Insider Trading Activity - Stock Titan
Fractyl Health reports one-year data on weight maintenance therapy - Investing.com UK
GUTS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Fractyl Health Reports Positive One-Year Results from REVEAL-1 Open-Label Study of Revita Procedure for Post-GLP-1 Weight Maintenance - marketscreener.com
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure - markets.businessinsider.com
Fractyl Health Highlights One-Year Revita Obesity Results - TipRanks
Fractyl Health reports one-year data on weight maintenance therapy By Investing.com - Investing.com South Africa
Fractyl Health Reports Positive One-Year Results from REVEAL-1 Cohort, Highlighting Revita's Efficacy in Sustaining Weight Loss Post-GLP-1 Therapy - Quiver Quantitative
Revita study shows durable post-GLP-1 weight loss at Fractyl Health (GUTS) - Stock Titan
Fractyl Health Reports Positive One-Year REVEAL-1 - GlobeNewswire
Fractyl Health names Mike Zumdahl as market access head By Investing.com - Investing.com South Africa
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy - The Manila Times
Fractyl Health names Mike Zumdahl as market access head - Investing.com
Nearly 1M leave GLP-1 therapy monthly; Fractyl hires market-access lead - Stock Titan
Fractyl Health, Inc. Announces Appointment of Mike Zumdahl to Senior Vice President, Market Access and Commercial Strategy - marketscreener.com
Fractyl Health Inc. (GUTS) Declines 2.7% as Stock Tests Critical Support Near $0.78Put Call Ratio - newsline.com
Fractyl Health (GUTS) Dips 3% as Stock Hovers Near Critical Support at $0.85Algorithmic Stock Picks - The Legal Advocate
GUTS Stock Chart | FRACTYL HEALTH INC (NASDAQ:GUTS) - ChartMill
Fractyl Health Q1 earnings call highlights - MSN
Fractyl Health Inc. (GUTS) Q1 2026 Earnings: Narrower Loss Surprises, Stock SlidesEarnings Cycle Report - thelegaladvocate.com
GUTS - Intellectia AI
Fractyl Health’s Pivotal Year: Inside the Earnings Call - TipRanks
Earnings call transcript: Fractyl Health Q1 2026 reports EPS beat, shares surge - Investing.com
Fractyl targets early Q4 2026 REMAIN-1 pivotal readout amid plans for late Q4 2026 de novo submission - MSN
Fractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit Turnaround - Yahoo Finance
First human GLP-1 gene therapy trial gets green light - NewsNation
Nantahala’s 16.1M-share stake disclosed in Fractyl Health (NASDAQ: GUTS) - Stock Titan
[SCHEDULE 13G/A] FRACTYL HEALTH, INC. Amended Passive Investment Disclosure - Stock Titan
BofA Securities Maintains Fractyl Health(GUTS.US) With Buy Rating, Announces Target Price $2 - Moomoo
Fractyl Health (GUTS) stock jumps 21% after hours: Here's what you should know - MSN
TradingKey - TradingKey
A Look At Fractyl Health (GUTS) Valuation After New Gene Therapy Trial Approval And First Quarter Net Income - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), UnitedHealth (UNH) and TELA Bio (TELA) - The Globe and Mail
SilverArc and Devesh Gandhi report 3.6M shares in Fractyl Health (GUTS) - Stock Titan
Fractyl Health Inc Stock (GUTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fractyl Health Inc Stock (GUTS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BRADLEY WILLIAM | Director |
Jun 10 '26 |
Buy |
0.73 |
68,493 |
50,329 |
84,622 |
| Sheffield Ian | Director |
Jun 10 '26 |
Buy |
0.73 |
35,000 |
25,529 |
35,000 |
| Rajagopalan Harith | Chief Executive Officer |
Jun 10 '26 |
Buy |
0.73 |
25,000 |
18,252 |
540,557 |
| Smith Weber Lara | Chief Financial Officer |
Jun 08 '26 |
Buy |
0.69 |
20,000 |
13,708 |
20,000 |
| Rajagopalan Harith | Chief Executive Officer |
Dec 04 '25 |
Buy |
1.92 |
10,416 |
19,999 |
501,745 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):